
Keywords: Clinical inertia; HbA1c; Oral glucose-lowering medication; Pharmacoepidemiology; Treatment intensification; Type 2 diabetes; Diabète de type 2; HbA1c; Inertie thérapeutique; Intensification du traitement; Médicaments hypoglycémiants oraux; Pharmaco-é